A new collaboration between TNO, Proefdiervrij, and pharmaceutical company Galapagos, called MechPath, is accelerating the transition to animal-free drug development. By combining patient data, lab-based human cell models, and artificial intelligence, the MECHanistic PATHology (MechPath) approach allows researchers to identify patterns and make reliable predictions without relying on animal testing.
Key results so far:
Human cells used in lab models appear to retain a “disease memory,” continuing to respond as if they were still in the body, offering more realistic models for conditions like fibrosis.
The newly developed CELLS-PATH validation tools help lab-grown models gain approval faster, paving the way for wider adoption in drug research.
Danish biotech start-up Fuse Vectors has launched its R&D operations in Leiden. From its new base at the Leiden Bio Science Park, the company is set to accelerate the...
LUdev is a student-run software company part of the Leiden Institute of Advanced Computer Science (LIACS) of Leiden University. The initiative gives bachelor's students the...
A month after being cleared to sell its animal-free meat fat in the US, Nourish Ingredients has set its sights on the global market with a new commercial hub in the Netherlands....